Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fewer Warning Letters: Does Change Point To FDA Advancement Or Decline?

This article was originally published in The Tan Sheet

Executive Summary

A growing preference for voluntary compliance from drug firms is one contributor to the "steady decrease in the number of CDER warning letters," according to FDAer Robert Maffei

Related Content

FDA enforcement declines – House report
Industry Input Will Bolster Risk-Based Inspection Approach – FDA’s Ellsworth
GMP Warning Letters: FDA Approves 55% Of Field Recommendations
Drug GMP Warning Letter Downtrend Accelerates In FY 2003
FDA GMP Initiative Shifts Warning Letter Review Back To Centers
FDA GMP Plan Stresses Consistency; Systems Approach Ratified By Crawford





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts